Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -3.57 is 270% below its 5-year average of 2.10, around the middle of its 5-year range (-25.91–26.98).
As of the fiscal period ended Tuesday, June 30, 2026. 168.74% below its 12-month average of 5.19.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -3.57.
DEBT TO EQUITY RATIO
-3.57
DEBT TO EQUITY RATIO AVG TTM
5.19
DEBT TO EQUITY RATIO AVG 3Y
2.35
DEBT TO EQUITY RATIO AVG 5Y
2.10
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-168.74%
CURRENT VS 3Y AVG
-251.68%
CURRENT VS 5Y AVG
-269.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-3343.70%
vs the sector median at left
Market Cap
$49.44M
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.04
5Y Avg
0.04
Market Cap
$48.89M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$49.47M
Debt to Equity Ratio
0.20
TTM Avg
0.18
3Y Avg
0.24
5Y Avg
0.23
Market Cap
$51.51M
Debt to Equity Ratio
0.00
TTM Avg
0.89
3Y Avg
0.55
5Y Avg
0.44
Market Cap
$50.57M
Debt to Equity Ratio
0.25
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TELA Bio, Inc. (TELA) | $49.21M | -3.57 | 5.19 | 2.35 | 2.10 |
| Apollomics, Inc. (APLM)vs › | $49.41M | N/A | 0.15 | 0.15 | 0.15 |
| Microbot Medical Inc. (MBOT)vs › | $49.44M | 0.01 | 0.02 | 0.04 | 0.04 |
| Sensus Healthcare, Inc. (SRTS)vs › | $48.89M | 0.01 | 0.01 | 0.02 | 0.02 |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.47M | 0.20 | 0.18 | 0.24 | 0.23 |
| INmune Bio, Inc. (INMB)vs › | $49.58M | 0.07 | 0.03 | 0.14 | 0.13 |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.51M | 0.00 | 0.89 | 0.55 | 0.44 |
| Envoy Medical, Inc. (COCH)vs › | $50.57M | 0.25 | 0.00 | 0.00 | 0.00 |
| Clene Inc. (CLNN)vs › | $50.81M | N/A | 6.12 | 6.71 | 4.67 |
| Lite Strategy, Inc. (LITS)vs › | $47.81M | 0.00 | 0.00 | 0.13 | 0.14 |
Debt/Equity
-3.57
Current Ratio
2.99
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -3.57 |
| 2026-03-31 | -10.84 |
| 2025-12-31 | 8.82 |
| 2025-09-30 | 26.98 |
| 2025-06-30 | 4.56 |
| 2025-03-31 | 2.31 |
| 2024-12-31 | 1.51 |
| 2024-09-30 | -6.62 |
| 2024-06-30 | 14.42 |
| 2024-03-31 | 2.87 |
| 2023-12-31 | 2.26 |
| 2023-09-30 | 1.37 |
| 2023-06-30 | 1.04 |
| 2023-03-31 | 13.24 |
| 2022-12-31 | 2.90 |
| 2022-09-30 | 1.72 |
| 2022-06-30 | -25.91 |
| 2022-03-31 | 3.19 |
| 2021-12-31 | 1.57 |
| 2021-09-30 | 1.13 |
| 2021-06-30 | 0.89 |
| 2021-03-31 | 0.74 |
| 2020-12-31 | 0.63 |
| 2020-09-30 | 0.54 |
| 2020-06-30 | 0.48 |
| 2020-03-31 | 1.25 |
| 2019-12-31 | 0.98 |
| 2019-09-30 | -0.19 |
| 2019-06-30 | -3.44 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | -0.22 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
